Blood cancers, Cell type, Chronic leukaemia, Chronic lymphocytic leukaemia (CLL), Leukaemia, Low grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)
Open
Phase 3
This trial is comparing nemtabrutinib with ibrutinib or acalabrutinib for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
It is for people who haven’t yet had treatment for CLL or SLL.
You pronounce nemtabrutinib as nem-ta-broo-ti-nib.
Recruitment start: 26 January 2024
Recruitment end: 19 July 2027
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Toby Eyre
Merck Sharp & Dohme Ltd
Last reviewed: 07 May 2025
CRUK internal database number: 19841
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
